MANIFOLD BIO
Live / Applied — Second extension granted (statement of use) (as of 12 Dec 2025)
What this means for you
Not registered yet, but its 22 Dec 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98328101
- Mark type
- Stylized text
- Filed
- 22 Dec 2023
- Published for opposition
- 17 Dec 2024
- Attorney of record
- Douglas R. Wolf
Goods and services
- Class 005 — Pharmaceuticals: biopharmaceuticals for cancer, neurological, metabolic, endocrine, gastrointestinal, respiratory, and autoimmune diseases, disorders, and conditions; biopharmaceutical preparations for prevention and treatment of cancer and neurological diseases, disorders, and conditions; biopharmaceutical preparations for prevention and treatment of, metabolic, endocrine, gastrointestinal, respiratory, and autoimmune diseases, disorders, and conditions
- Class 042 — Scientific and technological services: Biomedical research and development services; drug discovery in the field of biologics
Owner
- Manifold Biotechnologies, Inc., Boston, MA, US
- Manifold Biotechnologies, Inc., Boston, MA, US
Prosecution history
- 13 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Dec 2025 — SOU EXTENSION 2 GRANTED
- 12 Dec 2025 — SOU EXTENSION 2 FILED
- 12 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Feb 2025 — SOU EXTENSION 1 GRANTED
- 18 Feb 2025 — SOU EXTENSION 1 FILED
- 18 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Feb 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Dec 2024 — PUBLISHED FOR OPPOSITION
- 11 Dec 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Oct 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 23 Oct 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE